The SARS-CoV-2 virus
© BlackJack3D / Getty Images / iStock
In our Blog For the 2020 clinical trials day, we have summarized the COVID-19 studies that have been carried out so far on ISRCTN registration. A year later and it’s over now 170 COVID-19 studies registered. In this blog we look at the results of the platform Try our first blog and a selection of the repurposed drug treatment Attempts that have been started since then.
Platform trials compare multiple treatments simultaneously using a single protocol so that new treatments can be added and ineffective treatments dropped as the study progresses.
The World Health Organization (WHO) organized the international SOLIDARITY Study and found that treatment regimens with the reused antiviral drugs had remdesivir, hydroxychloroquine, lopinavir, and interferon little or no effect in hospitalized patients.
Great Britain RESTORATION Attempt is the world’s largest clinical study of treatments for COVID-19 with more than 30,000 participants in 177 trial sites at the time of writing. It turned out to be the most inexpensive steroid Dexamethasone reduces mortality by up to a third in hospitalized patients receiving invasive ventilation or oxygen.
Preliminary results also showed this Tocilizumab (a treatment for rheumatoid arthritis) too improves survival and other clinical outcomes. However, the antivirals are Lopinavir-ritonavir and Hydroxychloroquine, the antibiotic Azithromycin and Convalescent plasmadid not reduce mortality.The antiviral antibody cocktail REGN-COV2 and the anti-inflammatory drugs aspirin and colchicine have since been added RESTORATION.
The PRINCIPLE The study will test community treatments for suspected COVID-19 in the elderly and in patients with pre-existing medical conditions in general practitioners’ offices in England. They’re looking for treatments that will help people with COVID-19 symptoms recover quickly so they don’t have to go to the hospital.
Hydroxychloroquine was originally included in the study but was discontinued based on the results of the other studies. The antibiotics Azithromycin and Doxycycline were also found not to be generally effective. PRINCIPLE is currently testing the commonly used inhaled corticosteroid budesonide and that Anti-inflammatory Colchicine.
Other platform attempts
Other platform attempts include ACTT-EU / UKwho found this remdesivir shortened the time to recovery in hospitalized adults. ACCORD-2 is testing treatments such as Bemcentinib, MEDI-3506, Acalabrutinib, and Zilucoplan.
Our current knowledge of severe COVID-19 suggests that the immune system is over-activated in response to the infection, which can lead to organ damage.
Our current knowledge of severe COVID-19 suggests that the immune system is over-activated in response to the infection, which can lead to organ damage. Drugs approved for patients with autoimmune diseases such as rheumatoid arthritis and unlicensed drugs in trials for these conditions are tested to see if they can prevent this overactivation of the immune response.
The platform trial version REMAP-CAP found that immunomodulation with Tocilizumab and sarilumab improved critically ill patient outcomes including survival while CATALYST compares treatments including the monoclonal antibodies gemtuzumab ozogamicin, namilumab, and infliximab to see if they can reduce inflammation in the body caused by the virus.
Other monoclonal antibodies tested include adalimumab, which is being investigated in the EU AVID-CC Study to see if administration to patients outside the hospital can prevent progression of respiratory failure or death.
TACTIC-R Also, is recruiting patients at an early stage, when they begin to show mild pulmonary complications, to see if the reused drugs ravulizumab and baricitinib can prevent organ damage and reduce the need for intensive care and ventilation assistance.
Otilimab is being tested in the OSCAR Study specifically in patients at a later date who have developed severe pulmonary complications and require oxygen assistance or mechanical ventilation.
Several other antiviral drugs are in trials, including favipiravir – that GETAFIX One study is investigating whether giving patients with milder COVID-19 symptoms helps with their symptoms and reduces the time it takes to recover.
The IONIC One study is testing whether a combination of antiviral oseltamivir and a new drug (IMU-838) can reduce the time it takes to recover from COVID-19. SNG001, an inhaled drug containing the antiviral protein interferon-β, is being tested in the EU SPRINTER Study to see if it can speed recovery for hospital patients receiving oxygen.
Other reused drugs
Other drugs in trials are AlmitrineThis will be tested to see if it can improve blood oxygen levels and reduce the need for oxygen therapy and other forms of breathing assistance. The RECOVERED One study is looking at whether the antihypertensive drug losartan can improve patient outcomes.
The ILIAD-7-UK The study aims to find out whether the drug CYT107 will reduce mortality by reversing lymphopenia (in patients with abnormally low levels of white blood cells called lymphocytes) and T-cell depletion (which prevents the body from dealing with chronic viral infections) can.
The takeaway message
The ISRCTN registration continues to support global research on COVID-19 by giving priority to the immediate registration and reporting of COVID-19-related studies. All registered studies are made available worldwide by the WHO International platform for the registry of clinical trials (ICTRP) and all UK studies appear on Be part of the research.
By doing second part of this blog we are discussing the vaccine Studies and Studies of Tests and the Effects of COVID-19 on Other Conditions.